Gyre Therapeutics acquires Cullgen, creating a US-China integrated biopharma with a strong fibrosis-focused pipeline.

Gyre Therapeutics has completed its acquisition of Cullgen in an all-stock deal valued at about $300 million, forming a fully integrated biopharmaceutical company based in the US and China. The combined company now offers a commercial product, ETUARY®, for lung fibrosis in China, and a robust pipeline including treatments for liver fibrosis and inflammatory diseases. Leadership changes include Dr. Ying Luo becoming CEO and President, with Ping Zhang remaining Chairman. The acquisition strengthens Gyre's position with innovative targeted protein degrader therapies and supports future global growth, with ongoing clinical trials and regulatory progress in China and plans for expansion outside China, including the US.